STABStatera Biopharma, Inc.

About Statera Biopharma, Inc. (STAB)

Statera Biopharma, Inc. (STAB) is a Biotechnology company headquartered in Fort Collins, CO, United States whose shares trade over-the-counter on the Expert Market tier.

Statera Biopharma (formerly Cytocom, Inc.) is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. Statera has one of the largest platforms of toll-like receptor (TLR) agonists in the biopharmaceutical industry with TLR4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and GP532. TLRs are a class of protein that plays a key role in the innate immune system. Statera is developing therapies designed to directly elicit within patients a robust and durable response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. Statera has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401) and COVID-19 (STAT-205) in addition to potential expansion into fibromyalgia and multiple sclerosis. To learn more about Statera Biopharma, please visit www.staterabiopharma.com.

STAB key facts

Ticker symbol

STAB

Market tier

Expert Market

Sector

Healthcare

Industry

Biotechnology

Headquarters

Fort Collins, CO, United States

Country of incorporation

US

Year of incorporation

2003

Employees

21

Estimated market cap

$7.3K (as of Apr 11, 2025)

Shares outstanding

72,584,254

Reporting standard

U.S. Reporting: SEC Reporting

Audit status

Audited

Fiscal year end

12/31

Latest filing

8K Report (Jan 26, 2023)

Statera Biopharma, Inc. leadership

• Michael Kevin Handley — CEO, President
• Chris Zosh — CFO
• Robert Buckheit — CTO

Explore more: Biotechnology stocks · Healthcare sector · Expert Market stocks · OTC stocks starting with S